William Blair

Canaccord and William Blair also increased their price targets on  Quidel's shares, following its acquisition of certain Alere assets and assays.

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

In upgrading PacBio's shares to Outperform, the investment bank also took note of potential new revenues from its Roche deal and possibly a new platform launch next year.

The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.

Cowen & Co. upgraded Fluidigm to an Outperform rating, while William Blair upgraded Hologic also to Outperform. 

NEW YORK (GenomeWeb) – Investment bank William Blair today upgraded its rating for Sequenom's shares to Outperform on expectations of continued adoption of the molecular diagnostic firm's non-invasive prenatal testing technology and recent business developments that could increase revenues.

NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded Pacific Biosciences to a Neutral rating after the next-generation sequencing company announced better than expected placements of its instruments.

NEW YORK (GenomeWeb News) — William Blair today downgraded Sequenom after the San Diego-based company firm missed Wall Street estimates on the top and bottom lines in its second quarter.

NEW YORK (GenomeWeb News) – William Blair on Thursday initiated coverage of Waters, saying it believes the company can continue on its path of revenue growth and noting Waters consumables business and emerging market presence.

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer, investment firm William Blair today downgra

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.